Hambleton Julie
SEC insider (Form 3/4/5 filer). CIK 0001578771. Director at Erasca, Inc. (ERAS) and 2 other issuers. 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 26, 2026. Located in SAN DIEGO, CA.
Companies Hambleton Julie has filed insider reports for
- Erasca, Inc. (ERAS): Director
- IGM Biosciences, Inc. (IGMS): Director
- SpringWorks Therapeutics, Inc. (SWTX): Director
Hambleton Julie
CIK: 0001578771
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 26, 2026ERAS
Erasca, Inc.
AwardDirectStock option (right to buy)
29.9K shares- - Aug 14, 2025IGMS
IGM Biosciences, Inc.
DispositionDirect2K shares- - Jul 1, 2025SWTX
SpringWorks Therapeutics, Inc.
DispositionDirect14.2K shares- - Jun 24, 2025ERAS
Erasca, Inc.
AwardDirectStock option (right to buy)
120K shares- - May 14, 2025SWTX
SpringWorks Therapeutics, Inc.
AwardDirect10.1K shares- - Feb 10, 2025SWTX
SpringWorks Therapeutics, Inc.
SaleDirect13.8K shares at avg. $53.01$730K - Feb 10, 2025SWTX
SpringWorks Therapeutics, Inc.
ExerciseDirect13.8K shares at avg. $32.27$444K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 26, 2026 |  ERAS Erasca, Inc. | Award Stock option (right to buy) | 29,888 | - | - | Direct |
| Aug 14, 2025 |  IGMS IGM Biosciences, Inc. | Disposition | 2,000 | - | - | Direct |
| Jul 1, 2025 |  SWTX SpringWorks Therapeutics, Inc. | Disposition | 14,155 | - | - | Direct |
| Jun 24, 2025 | ERAS Erasca, Inc. | Award Stock option (right to buy) | 120,000 | - | - | Direct |
| May 14, 2025 | SWTX SpringWorks Therapeutics, Inc. | Award | 10,060 | - | - | Direct |
| Feb 10, 2025 | SWTX SpringWorks Therapeutics, Inc. | Sale | 13,774 | $53.01 | $730,207 | Direct |
| Feb 10, 2025 | SWTX SpringWorks Therapeutics, Inc. | Exercise | 13,774 | $32.27 | $444,487 | Direct |
1-7 of 7 transactions